Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of AP-101 in familial and sporadic amyotrophic lateral sclerosis
2020-005971-11Phase 2Active
- Sponsor
- AL-S Pharma AG
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing AP-101 with Placebo (2 arms). Primary endpoints: Safety and tolerability of AP-101, Pharmacodynamic markers of AP-101 and 1 more. Started Apr 2021; status: active.
02
Drugs
AP-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2020-005971-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005971-11.